z-logo
Premium
Therapeutic hypothermia in acute liver failure: A multicenter retrospective cohort analysis
Author(s) -
Karvellas Constantine J.,
Todd Stravitz R.,
Battenhouse Holly,
Lee William M.,
Schilsky Michael L.
Publication year - 2015
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.24021
Subject(s) - medicine , liver transplantation , acetaminophen , odds ratio , hepatic encephalopathy , gastroenterology , retrospective cohort study , confidence interval , liver disease , surgery , anesthesia , transplantation , cirrhosis
The benefit of therapeutic hypothermia (TH) in acute liver failure (ALF) has not been previously demonstrated in a controlled fashion. This study sought to determine the impact of TH on 21‐day survival and complications in ALF patients at high risk for cerebral edema. This was a retrospective cohort study of ALF patients in the US Acute Liver Failure Study Group with grade III or IV hepatic encephalopathy. TH (32°C‐35°C) was used in 97 patients (8%); 1135 (92%) who were not cooled were controls. Intracranial pressure was monitored in 38 TH ALF patients (39.2% versus 22% of controls, P  < 0.001). Rates of bleeding (12% for both) and bloodstream (17% versus 18%) and tracheal infections (21% versus 23%, P  > 0.5 for all) were similar. Unadjusted 21‐day overall (62% versus 60%) and transplant‐free survival rates (45% versus 39%, P  > 0.4 for both) were similar. Multivariate models were created for acetaminophen (APAP) patients (n = 582) and non‐APAP patients (n = 613). For APAP patients, the Model for End‐Stage Liver Disease [MELD; odds ratio (OR) = 0.91 per increment, 95% confidence interval (CI) = 0.89‐0.94, P  < 0.001] and vasopressors (OR = 0.16, 95% CI = 0.11‐0.24, P  < 0.001) were associated with decreased 21‐day spontaneous survival. Survival was improved with TH in APAP patients who were <25 years old (age of 25 years: OR = 2.735, 95% CI = 1.001‐7.467) but worsened for APAP patients who were 64 years old or older (age of 64 years: OR = 0.167, 95% CI = 0.028‐0.999). For non‐APAP patients, MELD (OR = 0.93 per increment, 95% CI = 0.91‐0.95, P  < 0.001) and vasopressors (OR = 0.60, 95% CI = 0.40‐0.90, P  = 0.01) were associated with worse outcomes, whereas TH had no impact ( P  = 0.93). In conclusion, TH in ALF was not associated with increased bleeding or infections. Although young APAP ALF patients may benefit, TH did not consistently affect 21‐day survival. A prospective trial is required to clarify the utility of TH in ALF patients. Liver Transpl 21:4‐12, 2015 . © 2014 AASLD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom